What bioidentical HRT actually means

Bioidentical hormones have a chemical structure that matches, or closely resembles, hormones the body naturally produces. For menopause care, this often includes estradiol, progesterone, and sometimes DHEA or testosterone in specific situations. However, the word bioidentical does not tell you whether the product has gone through FDA review.

Importantly, some FDA-approved hormone therapies are bioidentical. For example, clinicians may prescribe FDA-approved estradiol patches, gels, sprays, oral estradiol, vaginal estradiol, oral micronized progesterone, or vaginal DHEA. These products follow standardized manufacturing requirements and have data on dose, absorption, efficacy, and safety.

Compounded bioidentical HRT is different. Compounding pharmacies may custom-mix creams, capsules, gels, injections, or pellets. Although these products often use appealing language such as natural, customized, or hormone balancing, they generally do not receive FDA review for safety, effectiveness, potency, or quality before marketing.

Therefore, patients should ask a more specific question: Is this exact hormone therapy FDA-approved? That question matters more than the bioidentical label. A regulated estradiol patch and a custom compounded estrogen cream may both be called bioidentical, but they do not carry the same level of evidence or oversight.

What major medical organizations say about safety

Major medical organizations agree on a central point: compounded bioidentical HRT has not been proven safer or more effective than FDA-approved hormone therapy. The FDA states that compounded hormone products do not have evidence showing superior safety or effectiveness compared with approved options.

Additionally, the American College of Obstetricians and Gynecologists advises that clinicians should not routinely prescribe compounded bioidentical hormone therapy when FDA-approved formulations are available. This does not mean every compounded product causes harm. However, it does mean the evidence does not support using compounded therapy as the default choice.

The Menopause Society has also raised concerns about limited regulation, variable dosing, impurities, sterility issues, incomplete safety labeling, and lack of long-term outcome data. Similarly, the National Academies found insufficient evidence to support claims that compounded bioidentical hormones offer better clinical utility or superior safety.

In practical terms, the safest approach usually starts with an FDA-approved option when one can meet the patient’s needs. For example, a person who needs systemic estrogen may often use an approved estradiol patch, gel, spray, or pill. Meanwhile, a person with vaginal dryness may benefit from approved local vaginal therapy.

Why route, dose, and patient risk matter more than the label

When people ask whether bioidentical HRT is safer, they often want to know about blood clots, stroke, breast cancer, and other serious risks. However, safety depends on the hormone, dose, route, duration of use, age, time since menopause, and personal medical history. The label alone cannot answer those questions.

For blood clot risk, the route of estrogen appears especially important. Observational evidence suggests that transdermal estradiol, such as patches, gels, or sprays, may have a lower venous thromboembolism risk than oral estrogen. This likely relates to avoiding the first-pass effect through the liver.

However, transdermal estrogen is not risk-free. A person’s clot risk may also increase with obesity, smoking, thrombophilia, prior clots, immobility, older age, or certain medical conditions. Therefore, clinicians often individualize the route and dose rather than assuming that bioidentical automatically means low risk.

The same logic applies to compounded products. A compounded estrogen cream may be bioidentical, but compounding does not reduce clot risk by itself. Instead, the clinician must consider the actual estrogen exposure, route of delivery, dose consistency, and the patient’s baseline risk.

Micronized progesterone and breast or uterine safety

Micronized progesterone is an FDA-approved bioidentical option in many settings, and some evidence suggests it may have a more favorable breast-risk profile than certain synthetic progestins when combined with estrogen. For example, observational studies and meta-analyses have reported lower breast cancer risk with estrogen plus micronized progesterone compared with estrogen plus some synthetic progestins.

However, this does not prove that micronized progesterone prevents breast cancer. Much of the evidence comes from observational research, and long-term randomized comparisons remain limited. Additionally, breast risk can vary with age, family history, breast density, body weight, alcohol use, dose, duration, and the type of estrogen and progestogen used.

For people with a uterus, progesterone has another essential role. Systemic estrogen can stimulate the uterine lining, which may increase the risk of endometrial hyperplasia or endometrial cancer if estrogen is not balanced with adequate progestogen. Therefore, natural progesterone still needs the right dose and schedule.

Patients should report unexpected bleeding promptly, especially after menopause. In addition, clinicians should review the treatment plan if bleeding persists, symptoms do not improve, or side effects occur. Bioidentical HRT can be evidence-based when prescribed appropriately, but it still requires monitoring and thoughtful risk assessment.

Concerns with compounded creams, capsules, and pellets

Compounded bioidentical HRT raises several concerns that do not apply in the same way to FDA-approved therapies. First, potency can vary. Testing cited by ACOG found that compounded estradiol and progesterone products sometimes differed meaningfully from the labeled dose, with estradiol measured below the label claim and progesterone measured above it in some samples.

That variability matters clinically. Underdosing may leave hot flashes, night sweats, sleep disruption, or vaginal symptoms untreated. Conversely, excessive estrogen exposure may contribute to breast tenderness, bleeding, endometrial stimulation, mood changes, or other adverse effects. Inconsistent dosing also makes it harder to understand whether a treatment is truly working.

Additionally, absorption can vary with compounded creams and gels. Skin condition, application site, formulation, concentration, and manufacturing process can all affect exposure. FDA-approved products provide more predictable pharmacokinetic information, while custom products often have limited absorption data.

Pellets require special caution. Because pellets sit under the skin and release hormones for months, patients cannot easily stop exposure if the dose proves too high. Reported androgenic or pellet-related effects may include:

• Acne
• Increased facial or body hair
• Mood changes
• Weight gain
• Abnormal uterine bleeding
• Voice changes, which may be irreversible
• Insertion-site bleeding, infection, or extrusion

Saliva testing and hormone balancing claims

Many compounded bioidentical HRT programs promote saliva testing as a way to customize treatment. However, major medical organizations do not support routine salivary hormone testing for adjusting menopausal hormone therapy. ACOG states that saliva testing does not accurately or precisely measure clinically relevant estrogen or progesterone exposure.

Hormone levels naturally fluctuate, and saliva concentrations may not reflect tissue exposure or symptom burden. Additionally, there are no FDA-approved salivary or urinary tests for routine steroid-hormone dosing in menopausal treatment. Therefore, using these tests to fine-tune doses can create a false sense of precision.

In most cases, clinicians adjust menopausal hormone therapy by assessing symptoms, side effects, bleeding patterns, medical history, and risk factors. For example, improved hot flashes, better sleep, fewer night sweats, and stable bleeding patterns often provide more useful guidance than a hormone balancing panel.

Blood testing can help in selected circumstances. For instance, a clinician may check levels when evaluating possible excessive testosterone exposure or an unusual clinical concern. However, routine saliva testing does not make bioidentical HRT safer, and patients should be cautious when a clinic presents testing as proof of personalization.

When hormone therapy may help, and when it may not be appropriate

For appropriately selected patients, menopausal hormone therapy can work very well. It can reduce hot flashes, night sweats, and sleep disruption related to vasomotor symptoms. It can also help with vaginal dryness, painful sex related to tissue changes, and genitourinary symptoms. In some cases, it may help prevent bone loss.

The benefit-risk balance often looks more favorable for healthy women who start systemic therapy before age 60 or within 10 years of menopause onset. However, that timing principle does not replace individualized care. A person’s cardiovascular risk, clotting risk, migraine history, uterus status, cancer history, and personal goals all matter.

Systemic HRT may not be appropriate, or may require specialist input, for people with certain medical histories. These include:

• Breast cancer or certain hormone-sensitive cancers
• Unexplained vaginal bleeding
• Previous blood clots or pulmonary embolism
• Stroke or heart attack
• Significant liver disease
• Pregnancy

Additionally, hormone therapy should not be used solely to prevent heart disease, prevent dementia, reverse aging, remove wrinkles, or promote general weight loss. Although bioidentical HRT may improve menopause symptoms for the right patient, it is not an anti-aging treatment and should not be marketed as one.

A practical, evidence-based way to choose HRT

A thoughtful HRT plan starts with the treatment goal. For example, a patient with hot flashes and night sweats may need systemic therapy, while a patient with vaginal dryness alone may do well with a local vaginal option. Therefore, the best product depends on the symptom pattern and medical history.

When possible, clinicians should choose FDA-approved therapy that matches the patient’s needs. Approved bioidentical options exist, including estradiol and micronized progesterone. This means patients do not need to choose between evidence-based care and bioidentical hormones in many situations.

Compounded therapy may have a role in limited circumstances. For example, it may help when a patient has a documented allergy to an inactive ingredient, needs a dose or route that is not commercially available, or has another genuine formulation need. However, routine compounded bioidentical HRT is not recommended when approved options can meet the goal.

Before starting treatment, patients can ask practical questions:

• Is this product FDA-approved?
• What hormone, dose, and route am I receiving?
• If I have a uterus, how will my uterine lining be protected?
• What are my personal risks for clots, stroke, breast cancer, and endometrial cancer?
• How will we monitor benefits, side effects, and bleeding?
• Can I stop the treatment quickly if side effects occur?